Posted by Michael Wonder on 11 May 2020
Enhertu granted breakthrough therapy designation in the U.S. for HER2 positive metastatic gastric cancer
11 May 2020 - Designation based on data from pivotal phase 2 DESTINY-Gastric01 trial.
Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been granted breakthrough therapy designation in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of five percent for metastatic disease.
